Description

AstraZeneca’s Oncology Powerhouse Delivers 15% Growth As Enhertu Surges!

AstraZeneca’s first half and second quarter 2026 results demonstrated continued top-line momentum, with total revenue growing by 6% and core earnings per share (EPS) increasing by 11%, both underpinned by solid demand for innovative medicines and steady execution across diverse geographies. Excluding products facing generic competition such as Farxiga and Brilinta, revenue growth reached 11%, highlighting the underlying strength of the company’s portfolio. The company reported robust growth in its oncology and rare disease units, with oncology revenues expanding 15% driven by strong market uptake of key medicines including Tagrisso, Calquence, Imfinzi/Imjudo, and Enhertu, which posted a 31% increase. AstraZeneca’s broad oncology pipeline remains active with multiple Phase III readouts anticipated, alongside recently announced approvals for new molecular entities (NMEs) such as Etcamah and Baxfendy.